华领医药(02552.HK)完成糖尿病首创新药治疗III期临床试验
华领医药(02552.HK)为一家针对全球糖尿病患者尚未满足的临床需求研发全球原创新药的生物技术公司,今日(18日)公布旗下一款葡萄糖激(酉每)启动剂(GKA)首创新药Dorzagliatin的首个III期临床试验SEED(又称为HMM0301)的结果。
在28周开放性治疗期内,Dorzagliatin持续显示出良好的安全性和耐受性,这一结果也得到了安全性分析的验证。Dorzagliatin治疗组与安慰剂组的不良事件发生率相似,52周治疗期间内低血糖(血糖低於<3 mmol)发生率低於1%。28周开放治疗期间,作为2型糖尿病的主要标志的胰岛素抵抗指标持续性降低。
Dorzagliatin是一款葡萄糖激(酉每)启动剂(GKA)首创新药。52周试验在463名2型糖尿病患者中开展,旨在研究患者接受一天两次Dorzagliatin 75mg用药治疗的疗效和安全性,前24周为随机双盲、安慰剂对照治疗,用以评估Dorzagliatin的主要疗效终点和安全性,後28周为开放性药物治疗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.